CADL
Candel Therapeutics Inc
NASDAQ: CADL · HEALTHCARE · BIOTECHNOLOGY
$8.72
-8.20% today
Updated 2026-06-05
Market cap
$627.19M
P/E ratio
—
P/S ratio
436.42x
EPS (TTM)
$-1.01
Dividend yield
—
52W range
$4 – $10
Volume
1.9M
Candel Therapeutics Inc (CADL) Insider transactions
Net insider activity
Net buying (4,319,893 shares)
Buy transactions
43
Sell transactions
57
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-31 | PAPA, JOSEPH C | Director | Buy | 2,795 | $4.11 | $11498.63 |
| 2026-03-31 | MANNING, PAUL B | Director | Buy | 4,618 | $4.11 | $18998.45 |
| 2026-03-31 | LOGGIA, NICOLETTA | Director | Buy | 779 | $4.11 | $3204.81 |
| 2026-02-23 | MANNING, PAUL B | Director | Buy | 550,458 | $5.45 | $3.00M |
| 2026-01-26 | TYAGARAJAN, SESHU | Chief Technology Officer | Buy | 154,000 | — | — |
| 2026-01-26 | TAK, PAUL PETER | Director, Chief Executive Officer | Buy | 629,000 | — | — |
| 2026-01-26 | SCHOCH, CHARLES | Chief Financial Officer | Buy | 232,000 | — | — |
| 2026-01-26 | NICHOLS, WILLIAM GARRETT | Chief Medical Officer | Buy | 136,500 | — | — |
| 2026-01-26 | BARONE, FRANCESCA | Chief Scientific Officer | Buy | 232,000 | — | — |
| 2025-07-28 | NICHOLS, WILLIAM GARRETT | Chief Medical Officer | Sale | 937 | — | — |
| 2025-07-28 | NICHOLS, WILLIAM GARRETT | Chief Medical Officer | Sale | 937 | $6.98 | $6540.26 |
| 2025-06-30 | NICHOLS, WILLIAM GARRETT | Chief Medical Officer | Sale | 781 | — | — |
| 2025-06-30 | NICHOLS, WILLIAM GARRETT | Chief Medical Officer | Buy | 781 | $1.29 | $1007.49 |
| 2025-06-25 | TYAGARAJAN, SESHU | Chief Technology Officer | Buy | 5,353 | $4.67 | $24998.51 |
| 2025-06-25 | TAK, PAUL PETER | Director, Chief Executive Officer | Buy | 42,826 | $4.67 | $199997.42 |
| 2025-06-25 | SCHOCH, CHARLES | Chief Financial Officer | Buy | 5,353 | $4.67 | $24998.51 |
| 2025-06-25 | PAPA, JOSEPH C | Director | Buy | 64,239 | $4.67 | $299996.13 |
| 2025-06-25 | NABEL, GARY J. | Director | Buy | 5,353 | $4.67 | $24998.51 |
| 2025-06-25 | MARTELL, CHRISTOPHER | Director | Buy | 111,349 | $4.67 | $519999.83 |
| 2025-06-25 | MANNING, PAUL B | Director | Buy | 1,070,663 | $4.67 | $5.00M |
| 2025-06-25 | LOGGIA, NICOLETTA | Director | Buy | 2,141 | $4.67 | $9998.47 |
| 2025-06-25 | BARONE, FRANCESCA | Chief Scientific Officer | Buy | 4,282 | $4.67 | $19996.94 |
| 2025-06-20 | SCHOCH, CHARLES | Chief Financial Officer | Buy | 50,000 | — | — |
| 2025-06-17 | PAPA, JOSEPH C | Director | Buy | 14,240 | — | — |
| 2025-06-17 | NGUYEN, DIEM | Director | Buy | 14,240 | — | — |
| 2025-06-17 | NABEL, GARY J. | Director | Buy | 14,240 | — | — |
| 2025-06-17 | MARTELL, CHRISTOPHER | Director | Buy | 14,240 | — | — |
| 2025-06-17 | MANNING, PAUL B | Director | Buy | 14,240 | — | — |
| 2025-06-17 | LOGGIA, NICOLETTA | Director | Buy | 14,240 | — | — |
| 2025-06-17 | GAETA, RENEE | Director | Buy | 14,240 | — | — |
| 2025-06-17 | BENZ, EDWARD J. JR | Director | Buy | 14,240 | — | — |
| 2025-06-04 | RADHAKRISHNAN, MAHA | Director | Buy | 28,480 | — | — |
| 2025-03-19 | TAK, PAUL PETER | Director, Chief Executive Officer | Sale | 400 | $9.00 | $3601.00 |
| 2025-03-18 | TAK, PAUL PETER | Director, Chief Executive Officer | Sale | 25,772 | $8.77 | $226023.02 |
| 2025-03-18 | NICHOLS, WILLIAM GARRETT | Chief Medical Officer | Sale | 13,905 | — | — |
| 2025-03-18 | NICHOLS, WILLIAM GARRETT | Chief Medical Officer | Sale | 4,584 | — | — |
| 2025-03-18 | NICHOLS, WILLIAM GARRETT | Chief Medical Officer | Sale | 45,316 | $8.76 | $396995.35 |
| 2025-03-18 | NICHOLS, WILLIAM GARRETT | Chief Medical Officer | Buy | 13,905 | $1.29 | $17937.45 |
| 2025-03-18 | NICHOLS, WILLIAM GARRETT | Chief Medical Officer | Buy | 4,584 | $3.75 | $17190.00 |
| 2025-03-18 | BARONE, FRANCESCA | Chief Scientific Officer | Sale | 18,000 | — | — |
| 2025-03-18 | BARONE, FRANCESCA | Chief Scientific Officer | Sale | 32,146 | $8.76 | $281672.90 |
| 2025-03-18 | BARONE, FRANCESCA | Chief Scientific Officer | Buy | 18,000 | $1.55 | $27900.00 |
| 2025-03-17 | TYAGARAJAN, SESHU | Chief Technology Officer | Sale | 20,000 | — | — |
| 2025-03-17 | TYAGARAJAN, SESHU | Chief Technology Officer | Sale | 31,278 | $8.82 | $275947.03 |
| 2025-03-17 | TYAGARAJAN, SESHU | Chief Technology Officer | Buy | 20,000 | $1.29 | $25800.00 |
| 2025-03-17 | SCHOCH, CHARLES | See Remarks | Sale | 5,000 | $8.83 | $44169.00 |
| 2025-02-21 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 10,583 | $12.02 | $127207.66 |
| 2025-02-21 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 10,582 | $12.02 | $127195.64 |
| 2025-02-12 | TYAGARAJAN, SESHU | Chief Technology Officer | Buy | 65,000 | — | — |
| 2025-02-12 | TAK, PAUL PETER | Director, Chief Executive Officer | Buy | 525,000 | — | — |
| 2025-02-12 | SCHOCH, CHARLES | See Remarks | Buy | 83,000 | — | — |
| 2025-02-12 | NICHOLS, WILLIAM GARRETT | Chief Medical Officer | Buy | 107,250 | — | — |
| 2025-02-12 | BARONE, FRANCESCA | Chief Scientific Officer | Buy | 115,000 | — | — |
| 2025-02-10 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 31,335 | $8.61 | $269794.35 |
| 2025-01-15 | TYAGARAJAN, SESHU | Chief Technology Officer | Sale | 14,322 | $7.23 | $103476.45 |
| 2025-01-15 | TAK, PAUL PETER | Director, Chief Executive Officer | Sale | 21,704 | $7.23 | $156811.40 |
| 2025-01-15 | SCHOCH, CHARLES | See Remarks | Sale | 9,511 | $7.23 | $68716.97 |
| 2025-01-15 | NICHOLS, WILLIAM GARRETT | Chief Medical Officer | Sale | 10,428 | $7.23 | $75342.30 |
| 2025-01-15 | BARONE, FRANCESCA | Chief Scientific Officer | Sale | 13,534 | $7.23 | $97783.15 |
| 2025-01-08 | TYAGARAJAN, SESHU | Chief Technology Officer | Sale | 14,545 | $8.22 | $119533.72 |
| 2025-01-08 | TAK, PAUL PETER | Director, Chief Executive Officer | Sale | 21,172 | $8.22 | $173995.73 |
| 2025-01-08 | SCHOCH, CHARLES | See Remarks | Sale | 9,971 | $8.22 | $81943.67 |
| 2025-01-08 | NICHOLS, WILLIAM GARRETT | Chief Medical Officer | Sale | 10,799 | $8.22 | $88749.42 |
| 2025-01-08 | BARONE, FRANCESCA | Chief Scientific Officer | Sale | 13,673 | $8.22 | $112367.45 |
| 2024-12-27 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 50,000 | $8.85 | $442500.00 |
| 2024-12-26 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 50,000 | $9.01 | $450500.00 |
| 2024-12-24 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Buy | 50,000 | $8.82 | $441000.00 |
| 2024-12-23 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 50,000 | $8.52 | $426000.00 |
| 2024-12-20 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 100,000 | $9.00 | $900000.00 |
| 2024-12-16 | MANNING, PAUL B | Director | Buy | 750,000 | $6.00 | $4.50M |
| 2024-12-16 | MANNING, PAUL B | Director | Buy | 500,000 | $6.00 | $3.00M |
| 2024-12-12 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 200,000 | $10.04 | $2.01M |
| 2024-12-11 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 200,000 | $8.53 | $1.71M |
| 2024-12-06 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 20,000 | $5.23 | $104600.00 |
| 2024-12-05 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 20,000 | $4.79 | $95800.00 |
| 2024-12-04 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 20,000 | $4.46 | $89200.00 |
| 2024-11-29 | TYAGARAJAN, SESHU | Chief Technology Officer | Sale | 20,392 | $4.56 | $92897.80 |
| 2024-11-29 | TAK, PAUL PETER | Director, Chief Executive Officer | Sale | 48,847 | $4.56 | $222527.39 |
| 2024-11-29 | NICHOLS, WILLIAM GARRETT | Chief Medical Officer | Sale | 13,935 | $4.56 | $63482.29 |
| 2024-11-29 | BARONE, FRANCESCA | Chief Scientific Officer | Sale | 22,081 | $4.56 | $100592.20 |
| 2024-11-25 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 20,000 | $4.97 | $99400.00 |
| 2024-11-21 | TAK, PAUL PETER | Director, Chief Executive Officer | Sale | 12,900 | — | — |
| 2024-11-21 | TAK, PAUL PETER | Director, Chief Executive Officer | Buy | 12,900 | $1.55 | $19995.00 |
| 2024-11-08 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 7,500 | $4.92 | $36900.00 |
| 2024-11-07 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 7,500 | $5.19 | $38925.00 |
| 2024-11-06 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 7,500 | $5.33 | $39975.00 |
| 2024-11-01 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 7,500 | $5.27 | $39525.00 |
| 2024-10-31 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 7,500 | $5.30 | $39750.00 |
| 2024-10-30 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 6,000 | $5.38 | $32280.00 |
| 2024-10-28 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 11,711 | $5.58 | $65347.38 |
| 2024-10-25 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 1,597 | $5.80 | $9262.60 |
| 2024-10-24 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 16,427 | $5.53 | $90841.31 |
| 2024-10-24 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 1,194 | $5.72 | $6829.68 |
| 2024-10-15 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 10,412 | $6.03 | $62784.36 |
| 2024-10-14 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 15,000 | $6.02 | $90300.00 |
| 2024-10-11 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 15,000 | $6.05 | $90750.00 |
| 2024-10-03 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 1,800 | $6.85 | $12330.00 |
| 2024-10-02 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Sale | 26,988 | $6.92 | $186756.96 |
| 2024-10-01 | AGUILAR-CORDOVA, ESTUARDO | 10% Owner | Buy | 6,214 | $7.01 | $43554.55 |
| 2024-07-17 | TYAGARAJAN, SESHU | Chief Technology Officer | Sale | 14,851 | $6.47 | $96124.58 |
Frequently asked questions
Are CADL insiders buying or selling?
Over the transactions on record, CADL insiders have been net sellers, with about $10.58M in stock sold across 57 sales, against 23 open-market purchases.
Does insider selling at CADL mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which CADL insiders are selling the most?
Recent selling is concentrated in a few names. AGUILAR-CORDOVA, ESTUARDO accounts for the largest share on record, with about $7.69M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.